small molecule

SCENESSE

AFAMELANOTIDE

Loss of exclusivityJanuary 2033latest FDA-listed patent expiry

CompanyClinuvel Pharmaceuticals Ltd →See this company's full patent-cliff portfolio

Drug detail

Brand name	SCENESSE
Active ingredient	AFAMELANOTIDE
Strength	16MG
Dosage form	IMPLANT
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	October 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
8334265	January 2033	use U-2638

Regulatory exclusivity

Code	Expires
ODE-270	October 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.